Patients in the phase 3 LIBREXIA ACS trial showed no reduction in cardiovascular events after acute coronary syndrome.

Statin use for primary cardiovascular prevention in adults aged 70 years or older is supported by data from STAREE, although treatment did not prolong disability-free survival.

Despite a major reduction in transthyretin amyloid deposits, eplontersen, a drug that reduces TTR production, did not reduce events associated with TTR amyloidosis in a phase 3 trial.

A novel ultrasound-derived score combined with liver stiffness measurement can identify both MASH and fibrosis, potentially ...

Visible hyperpigmentation may mask persistent erythema and should not be assumed to indicate resolved inflammation,’ ...

Hallmark signs of pediatric pneumonia, including crackles and decreased breath sounds, shows low reliability between ...

Lumbar CT attenuation measurements outperform MRI-derived vertebral bone quality scores for diagnosing osteopenia and ...

A prospective study shows that lower levels of physical exercise are consistently associated with a higher risk for common ...

Anticoagulation reduced adverse clinical events in patients with atrial fibrillation at intermediate stroke risk, without an ...

The assay’s significant limitation is its inability to assess drug resistance for integrase inhibitors, including ...

In a phase 3 trial, adding a combo of two traditional Chinese meds to metformin reduced A1c and improved lipid measure in ...

Laser interstitial thermal therapy (LITT) demonstrates low complication rates in a study of nearly 800 patients with brain ...